HomeAI · summaries
Storia in 2 fonti
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales
India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moderating. Doctors note that physician training and patient education are now crucial for future market expansion. Meanwhile, tirzepatide shows a recovery, maintaining its market position. Competition remains intense with numerous semaglutide brands.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
thehindubusinessline.com
Generic semaglutide race hinges on API supply as China leads: Goldman Sachs
The big unknown is whether CDMO capacity built for branded drugs gets diverted to generics, and whether SPPS can scale fast enough to meet a market Goldman models at ~99,000 kg of…
- ·
economictimes.indiatimes.com
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales
India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moderating. Doctors note that physician…
